Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models

BACKGROUND: Sorafenib is recognized as a standard treatment for advanced hepatocellular carcinoma (HCC). However, many patients have to adopt dose reduction or terminate the use of sorafenib because of side effects. In addition, a large number of patients are resistant to sorafenib. Thus, it is esse...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Hematol Oncol
Hlavní autoři: You, Abin, Cao, Manqing, Guo, Zhigui, Zuo, Bingfeng, Gao, Junrong, Zhou, Hongyuan, Li, Huikai, Cui, Yunlong, Fang, Feng, Zhang, Wei, Song, Tianqiang, Li, Qiang, Zhu, Xiaolin, Yin, Haifang, Sun, Huichuan, Zhang, Ti
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2016
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4784359/
https://ncbi.nlm.nih.gov/pubmed/26957312
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0253-6
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky